587 7. Oltre il Trapianto Bibliografia 1. CAR T-Cell Therapy: Updates in Nursing Management Brittney Baer CJON 2021, 25(3), 255-258 DOI: 10.1188/21.CJON.255-258 2. Cell Therapy Open Source Le Terapie CAR T, dal laboratorio al paziente Volume 1° novembre 2020, Rarelab Srl edizione Armeni P, Ceradini F, Corradini P, Fagioli F, Iannelli E, Jommi C, Locatelli F, Mantovani A, Nardi S, Nolli M.L, Orzes E, Pennisi M, Petruzzelli D, Pompilio G, Saccardi R, Tognaccini C, Villa R, Zinzani P.L 3. L. Orlando, G. Nepoti, Le terapie cellulari CAR-T. Competenza infermieristica, Assistenza infermieristica, Responsabilità multidisciplinare, Terapie geniche Bononia University Luglio 2021 4. Management Across Settings An ambulatory and community perspective for patients undergoing CAR T-cell therapy in multiple care settings Alix Beaupierre, BSN, RN, OCN®, Rachel Lundberg, PA-C, Leslie Marrero, BSN, RN, OCN®, BMTCN®, Michael Jain, MD, PhD, Trent Wang, DO, MPH, and Maritza C. Alencar, DNP, MBA, APRN-BC, BMTCN® SUPPLEMENT TO APRIL 2019, VOL. 23, NO. 2 CLINICAL JOURNAL OF ONCOLOGY NURSING 27-34 5. Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, Corbacaioglu S, Duarte RF, Einsele H, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Robinson S, Saccardi R, Sanchez-Guijo F, Snowden JA, Srour M, Styczynski J, Urbano-Ispizua A, Hayden PJ, Kröger N. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and and the Joint Accreditation Committee of ISCT and EBMT (JACIE) 6. Taylor, L. Rodriguez, E. Reese, A. & Anderson, K. (2019). Building a program: Implications for infrastructure, nursing education, and training for CAR T-cell therapy. Clinical Journal of Oncology Nursing, 23(Suppl. 1), 20–26 7. A. Cordeiro, Evandro D. Bezerra, MD4, Alexandre V. Hirayama, Joshua A. Hill, Vicky Wu, Jenna Voutsinas, Mohamed Sorror, Cameron J. Turtle, David G. Maloney, Merav Bar, Late events after treatment with CD19-Targeted Chimeric Antigen Receptor Modified T-cells Biol Blood Marrow Transplant. 2020 January ; 26(1): 26–33. doi:10.1016/j.bbmt.2019.08.003. 8. Gust J, Ponce R, Liles WC, et al. Cytokines in CAR T cell-associated neurotoxicity. Front Immunol 2020; 11:577027. doi: 10.3389/ fimmu.2020.577027 9. Beaupierre A, Lundberg R, Marrero L, et al. Management across settings: an ambulatory and community perspective for patients undergoing CAR T-cell therapy in multiple care settings. Clin J Onc Nurs 2019; 23(Suppl):27-34 10. Kymriah 2021. Summary of Product Characteristics. Disponibile all‘indirizzo: https://www.ema.europa.eu/en/ documents/product-information/kymriah-epar-product-information_en.pdf. Accesso maggio 20 11. Anderson K, Latchford T. Tossicità associate: valutazione e gestione relative alla terapia con cellule CAR-T. Clin J Oncol Nrsg 2019; 23:13-19 12. Brudno JN, Kochenderfer JN. Recent advances in CAR-T-cell toxicity: mechanisms, manifestations and management. Blood Rev 2019; 34:45-55 13. Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol 2018; 15:47-62 14. Santomasso BD, Park JH, Salloum D, et al. Clinical and biological correlates of neurotoxicity associated with Car T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov 2018; 8:958-971 15. Shah NN, Johnson BD, Fenske TS, et al. Intrathecal chemotherapy for management of steroid-refractory CAR-T-cell associated neurotoxicity syndrome. Blood Adv 2020; 4:2119-2122 16. Rivera AM, May S, Lei M, et al. CAR-T-cell-associated neurotoxicity: current management and emerging treatment strategies. Crit Care Nurs Q 2020; 43:191-204 17. Yakoub-Agha I, Chabannon C, Bader P, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica 2018; 105:297-316
RkJQdWJsaXNoZXIy ODUzNzk5